Takeda acquired LigoCyte Pharmaceuticals for $60 million, with potential future payouts that were undisclosed.
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales.
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales. Take a look at the full list >>
A few new Salmonella Typhi vaccines use live attenuated strains of the bacteria, but such methods can mean the salmonella is shed into the environment through excrement. Researchers at Arizona State University's Biodesign Institute have been researching ways to detect S. Typhi--the cause of typhoid fever--in feces after use of the vaccine.
There is currently no chlamydia vaccine, but an Indiana University researcher has been given $2.3 million to try to create one.
It's understandable that kids don't like getting shots, but you would think that the grown-ups know what's good for them. Not so, perhaps--a recent report from the national Centers for...
In a 14-1 vote, a panel of FDA experts say Pfizer's ($PFE) Prevnar 13 protected adults over 50 from pneumococcal infections, paving the way for a likely approval in January. Earlier this week agency
Five years ago, Merck gained FDA approval for its shingles prevention vaccine Zostavax. The agency recently expanded that approval to adults 50 years and older. Yet vaccination rates remain low due
Keeping up-to-date with adult vaccines can cut down on future healthcare costs, according to a report published by the AP. But there are several factors standing in the way of regular immunizations.